Journal of Ophthalmology

Rho Kinase in Eye Disease


Status
Published

Lead Editor

1Doshisha University, Kyoto, Japan

2Kyushu University, Fukuoka, Japan

3Kumamoto University, Kumamoto, Japan

4Case Western Reserve University, Cleveland, USA


Rho Kinase in Eye Disease

Description

Rho-associated protein kinase (ROCK) is a well-characterized effector of Rho GTPase. The Rho/ROCK signaling pathways contribute to a wide range of fundamental cell functions, such as cell adhesion, motility, proliferation, differentiation, and apoptosis. Due to its role in controlling a wide spectrum of biological events, ROCK has been intensively investigated as an important therapeutic target in a wide range of diseases including vascular disease, cancer, neuronal degenerative disease, asthma, and glaucoma. One ROCK inhibitor, fasudil, was approved for the treatment of cerebral vasospasm in 1995. In 2014, another ROCK inhibitor, ripasudil, was approved in Japan for the treatment of glaucoma and ocular hypertension. These monumental achievements have opened the pathway towards the clinical application of ROCK inhibitor as a therapeutic modality in the field of ophthalmology.

In addition to glaucoma, the involvement of ROCK signaling has been researched in other eye diseases such as corneal endothelial disease, cataract, age-related macular degeneration, and proliferative vitreous retinopathy. Thus, there is growing evidence that ROCK inhibitor might be a promising therapeutic modality in various eye diseases.

Therefore, we became interested in reports on the involvement of ROCK signaling in pathological situations and the possible application of ROCK inhibitor as a drug for treating eye-related disease. This special issue will provide a platform for readers to discover the importance and possible future application of ROCK inhibitor as a cross-sectional topic.

Potential topics include but are not limited to the following:

  • Diseases: corneal endothelial disease, cataract, age-related macular degeneration, and proliferative vitreous retinopathy
  • The involvement of Rho/ROCK signaling in eye diseases
  • The feasibility of ROCK inhibition for treating eye diseases
  • The application of ROCK inhibitor as adjunctive drug for eye surgery
  • Clinical data pertaining to ROCK inhibitor eye drops in glaucoma patients

Articles

  • Special Issue
  • - Volume 2017
  • - Article ID 9281745
  • - Editorial

Rho Kinase in Eye Disease

Naoki Okumura | Shintaro Nakao | ... | Padmanabhan Pattabiraman
  • Special Issue
  • - Volume 2017
  • - Article ID 1598218
  • - Research Article

Development of Poly Lactic/Glycolic Acid (PLGA) Microspheres for Controlled Release of Rho-Associated Kinase Inhibitor

Sho Koda | Naoki Okumura | ... | Yasuhiko Tabata
  • Special Issue
  • - Volume 2017
  • - Article ID 8653130
  • - Research Article

Effects of the Rho-Kinase Inhibitor Y-27632 on Extraocular Muscle Surgery in Rabbits

Ji‐Sun Moon | Hyun Kyung Kim | Sun Young Shin
  • Special Issue
  • - Volume 2017
  • - Article ID 8543592
  • - Review Article

Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases

Muneo Yamaguchi | Shintaro Nakao | ... | Koh-hei Sonoda
  • Special Issue
  • - Volume 2017
  • - Article ID 5614089
  • - Research Article

A Surgical Cryoprobe for Targeted Transcorneal Freezing and Endothelial Cell Removal

Alina Akhbanbetova | Shinichiro Nakano | ... | Andrew J. Quantock
  • Special Issue
  • - Volume 2017
  • - Article ID 7079645
  • - Research Article

Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys

Yoshio Kaneko | Masayuki Ohta | ... | Ken Mizuno
Journal of Ophthalmology
 Journal metrics
Acceptance rate36%
Submission to final decision74 days
Acceptance to publication31 days
CiteScore2.800
Impact Factor1.447
 Submit